ADCT – Adc Therapeutics SA
ADC Therapeutics SAADCT
$3.52Name : ADC Therapeutics SA
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $436,047,424.00
EPSttm : -1.41
ADC Therapeutics SA
$3.52
0.28%$0.01Float Short %
6.64
Margin Of Safety %
Put/Call OI Ratio
0.3
EPS Next Q Diff
0.02
EPS Last/This Y
0.21
EPS This/Next Y
0.3
Price
3.52
Target Price
8
Analyst Recom
1
Performance Q
-11.56
Relative Volume
0.48
Beta
1.95
Ticker: ADCT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-08 | ADCT | 3.22 | 0.02 | 0.00 | 32823 |
| 2025-12-09 | ADCT | 3.54 | 0.02 | 0.00 | 32829 |
| 2025-12-10 | ADCT | 4.03 | 0.02 | 0.01 | 32858 |
| 2025-12-11 | ADCT | 4.19 | 0.02 | 0.00 | 32867 |
| 2025-12-12 | ADCT | 4.24 | 0.02 | 0.00 | 32865 |
| 2025-12-15 | ADCT | 4.2 | 0.04 | 1.00 | 17864 |
| 2025-12-16 | ADCT | 3.99 | 0.04 | 0.00 | 17865 |
| 2025-12-17 | ADCT | 3.68 | 0.04 | 0.01 | 17893 |
| 2025-12-18 | ADCT | 3.9 | 0.04 | 2.36 | 18033 |
| 2025-12-19 | ADCT | 3.72 | 0.04 | 0.00 | 18150 |
| 2025-12-22 | ADCT | 3.69 | 0.31 | 0.00 | 2973 |
| 2025-12-23 | ADCT | 3.5 | 0.31 | 0.05 | 2980 |
| 2025-12-26 | ADCT | 3.5 | 0.30 | 0.67 | 3047 |
| 2025-12-29 | ADCT | 3.51 | 0.30 | 0.00 | 3048 |
| 2025-12-30 | ADCT | 3.5 | 0.30 | 0.00 | 3053 |
| 2025-12-31 | ADCT | 3.54 | 0.30 | 999.99 | 3096 |
| 2026-01-02 | ADCT | 3.52 | 0.30 | 0.25 | 3095 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-08 | ADCT | 3.22 | - | - | -1.41 |
| 2025-12-09 | ADCT | 3.53 | - | - | -1.41 |
| 2025-12-10 | ADCT | 4.02 | - | - | -1.41 |
| 2025-12-11 | ADCT | 4.18 | - | - | -1.41 |
| 2025-12-12 | ADCT | 4.22 | - | - | -1.41 |
| 2025-12-15 | ADCT | 4.21 | - | - | -1.41 |
| 2025-12-16 | ADCT | 4.21 | - | - | -1.41 |
| 2025-12-17 | ADCT | 3.68 | - | - | -1.41 |
| 2025-12-18 | ADCT | 3.90 | - | - | -1.41 |
| 2025-12-19 | ADCT | 3.73 | - | - | -1.41 |
| 2025-12-22 | ADCT | 3.76 | - | - | -1.41 |
| 2025-12-23 | ADCT | 3.51 | - | - | -1.41 |
| 2025-12-26 | ADCT | 3.50 | - | - | -1.41 |
| 2025-12-29 | ADCT | 3.51 | - | - | -1.41 |
| 2025-12-30 | ADCT | 3.50 | - | - | -1.41 |
| 2025-12-31 | ADCT | 3.54 | - | - | -1.41 |
| 2026-01-02 | ADCT | 3.52 | - | - | -1.41 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-08 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-09 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-10 | ADCT | 0.00 | 1.77 | 6.07 |
| 2025-12-11 | ADCT | 0.00 | 1.77 | 6.07 |
| 2025-12-12 | ADCT | 0.00 | 1.77 | 6.07 |
| 2025-12-15 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-16 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-17 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-18 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-19 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-22 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-23 | ADCT | 0.00 | 1.77 | 5.91 |
| 2025-12-26 | ADCT | 0.00 | 1.77 | 6.64 |
| 2025-12-29 | ADCT | 0.00 | 1.77 | 6.64 |
| 2025-12-30 | ADCT | 0.00 | 1.77 | 6.64 |
| 2025-12-31 | ADCT | 0.00 | 1.77 | 6.64 |
| 2026-01-02 | ADCT | 0.00 | 1.77 | 6.64 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.3
Avg. EPS Est. Current Quarter
-0.29
Avg. EPS Est. Next Quarter
-0.28
Insider Transactions
Institutional Transactions
1.77
Beta
1.95
Average Sales Estimate Current Quarter
18
Average Sales Estimate Next Quarter
19
Fair Value
Quality Score
70
Growth Score
27
Sentiment Score
58
Actual DrawDown %
89.8
Max Drawdown 5-Year %
-98.6
Target Price
8
P/E
Forward P/E
PEG
P/S
5.8
P/B
P/Free Cash Flow
EPS
-1.45
Average EPS Est. Cur. Y
-1.41
EPS Next Y. (Est.)
-1.11
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-221.97
Relative Volume
0.48
Return on Equity vs Sector %
42.8
Return on Equity vs Industry %
58.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.11
EBIT Estimation
ADC Therapeutics SASector: Healthcare
Industry: Biotechnology
Employees: 263
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
stock quote shares ADCT – Adc Therapeutics SA Stock Price stock today
news today ADCT – Adc Therapeutics SA stock forecast ,stock prediction 2023 2024 2025
marketwatch ADCT – Adc Therapeutics SA yahoo finance google finance
stock history ADCT – Adc Therapeutics SA invest stock market
stock prices ADCT premarket after hours
ticker ADCT fair value insiders trading